by Kinnate Biopharma | May 27, 2020 | News
Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer Company further expands executive leadership with the appointment of Mark Meltz as Chief Operating Officer and General Counsel SAN DIEGO, Calif. — May 27, 2020 — Kinnate Biopharma Inc., a precision...
by Kinnate Biopharma | Dec 19, 2019 | News
Kinnate Biopharma Closes $74.5M Series B Financing New investors OrbiMed, Nextech Invest and Vida Ventures join existing investors Foresite Capital and Eshelman Ventures. Proceeds will be used to advance multiple precision oncology drug candidates into the clinic. SAN...
by Kinnate Biopharma | Apr 11, 2018 | News
Fount Therapeutics Secures $22M Series A Financing Fount Therapeutics secures $22 million Series A financing from Foresite Capital and Eshelman Ventures. The funds will establish multiple subsidiary R&D companies to develop treatments in various therapeutic areas....
Recent Comments